PB
Pangea Bio
United Kingdom · Biotech
Pangea Bio develops medicines for central nervous system disorders.
Product
Pangea Bio is a clinical-stage biotechnology company developing therapies focused on neuroplasticity. Its research targets the TrkB receptor pathway, with lead candidate OT-003 and follow-on compounds.
The London company works on treatments for neurological and neuropsychiatric conditions. It builds its drug discovery programme around molecules inspired by natural biology.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| One Mind Accelerator investment | $100K | One Mind — Participant |